Dr. Tedesco discusses first immunotherapy regimen for breast cancer
Karen Tedesco, MD, was recently featured on the American Society of Clinical Oncology's national "Daily News" podcast. She discusses the advancement in breast cancer treatment that came earlier this year, when the FDA granted accelerated approval to atezolizumab, the first cancer immunotherapy regimen for breast cancer.
In addition to treating patients, Karen Tedesco, MD, also serves as principal investigator at NYOH for clinical trials related to breast cancer treatment. In the nine-minute podcast, she also discusses how the IMpassion 130 study will continue to inform treatment of metastatic triple negative breast cancer.